AACR 2025 Posters: Sneak Peek
From April 25 to 30, 2025, the annual meeting of the American Association for Cancer Research (AACR), one of the...
Continue ReadingKnowledge Library
Therapeutic Potential of Polatuzumab Vedotin for the Treatment of DLBCL
Approximately 20-40% of diffuse large B-cell lymphoma (DLBCL) patients experience relapsed or refractory disease after initial treatment with R-CHOP (a...
Continue Reading
Developing Resistant Models to Diverse ADC Drugs
Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer...
Continue Reading
Targeting FAK Improves the Tumor Uptake of ADCs
Antibody-drug conjugates (ADCs), exemplified by HER2-targeted Enhertu and TROP2-targeted Trodelvy, have demonstrated significant therapeutic potential in cancers. However, a subset...
Continue Reading
Strategies to Accelerate the Development of Antibody-Drug Conjugates
Antibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics, but their complex structure poses significant development and safety challenges...
Continue Reading Custom Antibody and Protein Preparation Services
WuXi AppTec provides integrated and cost-effective services for: Polyclonal and monoclonal antibodies Anti-drug antibodies (ADA), host cell protein (HCP) antibodies,...
Continue Reading T-DXd Resistant Tumor Models with ABCG2
Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer...
Continue Reading Pioneering Advanced Modalities in Early Drug Discovery
New modalities such as peptides, oligonucleotides, and cell and gene therapies have revolutionized healthcare industry innovation. To meet these evolving...
Continue Reading
Enhertu-Induced Resistant Tumor Models
Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer...
Continue Reading